652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
Kathryn C. Arbour(Memorial Sloan Kettering Cancer Center), Salman R. Punekar(Columbia University Irving Medical Center), Ignacio Garrido‐Laguna(University of Utah), David S. Hong(The University of Texas MD Anderson Cancer Center), Brian M. Wolpin(Dana-Farber Cancer Institute), Meredith S. Pelster(Sarah Cannon), M. Barve(Mary Crowley Cancer Research Center), Alexander Starodub(Christ Hospital), D. Sommerhalder, Sam S. Chang(Revolution Medicines (United States)), Y. Zhang(Revolution Medicines (United States)), Zeena Salman(Revolution Medicines (United States)), X. Wang(Revolution Medicines (United States)), Corinne E. Gustafson(Revolution Medicines (United States)), Alexander I. Spira(Virginia Cancer Specialists)
Cited by 113Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis